Reducing Neutropenia Incidence by Changing the Date of Eflapegrastim Administration in Breast Cancer Patients Who Have Experienced Neutropenia After Chemotherapy
Patients who experienced neutropenia after receiving pegfilgrastim on day 1 of the first round are randomly assigned to either the control or experimental arm. Patients in the control arm continue pegfilgrastim injection on day 1 while patients in the experimental arm will receive pegfilgrastim injection on day 3 to see if changing the pegfilgrastim administration date from day 1 to day 3 starting from the second round of chemotherapy could reduce the incidence of neutropenia
• Women aged 18 to 75 years old as of the date of study registration.
• Patients with histologically confirmed invasive adenocarcinoma.
• Patients with confirmed estrogen receptor, progesterone receptor, and Her2 receptor status.
• Patients with Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
• Patients with a left ventricular ejection fraction (LVEF) ≥55%.
• Patients who have agreed to participate in this trial and have provided written consent.